Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italian developer of innovative eye care solutions S.I.F.I. and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.
Subscribe to our email newsletter
The products include prescription drugs to treat patients undergoing ocular interventions or suffering from infections or inflammatory diseases of the eye.
In particular, the portfolio includes two artificial tear formulations, Eyestil and Lacrisifi, developed to treat dry eye conditions resulting from altered or reduced tear production. Additionally, ColbiocinM, Nettavisc and Nettacin offer three antibiotic options, available in multiple dosage forms, for the treatment of external eye infections.
Prenacid is a water-soluble corticosteroid indicated for treatment of inflammations, including post-surgical inflammations, and allergies. Octilia is an eye drop solution indicated for treatment of irritations, reddening, ocular congestion and pruritus due to allergic, chemical or physical causes.
Lastly, MirtileneForte is a retinotrophic with a vasoprotective action helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.
All the drugs have undergone clinical studies and are registered in Russia and the EU. NovaMedica plans to initiate sales of some of these products in Russia later this 2014.
NovaMedica COO Fabrice Egros noted combined with other advanced pharmaceuticals already in the company’s pipeline, the SIFI products contribute to the creation of a balanced NovaMedica portfolio with drugs and therapies in place to meet the needs of both ophthalmologists and patients across a wide variety of ocular conditions.
"This partnership enables us to quickly bring the latest therapies in the ophthalmology sector to Russian patients, a key element serving our short- and long-term strategy," Egros added.